[START RECORDING]

SAJID AHMED:**[00:00;00]** So, ahm let's go around the room and just kind of introduce ahm ourselves. So, ahm Ben, why don't we start off with you?

BEN ROOSZ: Yeah, sure. So I'm Ben Roosz, I'm with ah Eli Lilly, and so I'm a global brand manager on the Selpercatinib team.

ANDREW GIANOUKAKIS: Andrew Gianoukakis, endocrinologist, Harbor, UCLA, Los Angeles.

JANE WHITE: I'm Jane white, I'm the oncology diagnostics MSL covering the southeastern US.**[00:00:30]**

JENNIFER SIPOS: Jeniffer Sipos summit, Ohio State university. Endocrinology.

BRIAN CHOU: Brian Chou, Eli lilly US marketing strategy.

MARK LUPO: Mark Lupo endocrinologist in Sarasota, Florida.

PABLO LILLY: Pablo Lilly, I'm the US and global ah global ah US and global medical affairs lead.

ZSOFIA GECK: **[00:01:00]**Zsofia Geck. I'm an endocrinologist in Sarasota County.

WOODY SISTRUNK: Woody Sistrunk I'm an endocrinologist in Jackson, Mississippi.

SUSAN MARCHAND: Susan Marchand I live in Charlotte, North Carolina with Eli Lilly and one of the directors of the Lilly Msls.

BRYAN MCIVER: Byan Mciver. I'm an endocrine oncologist at Moffitt Cancer Center in Tampa, Florida.

SAJID AHMED: And I'm Sajid Ahmed. I'm part of the Selpercatinib medical affairs team for Loxo/oncology.

BRIAN: Yeah. **[00:01:30]**So you've actually the perfect segue to the next question about the use of molecular classifiers. Is there an opportunity if a point mutation or fusion was detected using one of the using the one that is not RNA expression based, would that be an opportunity to spare the patient a surgery?

[END RECORDING]